Brief: Biosyent Q3 EPS C$0.08
23/11/2016 13:00
Nov 23 (Reuters) - Biosyent Inc RX.V :
* "expect to see significant growth in 2016 international
pharmaceutical sales over 2015"
* Biosyent releases results for third quarter and first nine
months of 2016
* Q3 revenue rose 3 percent to C$4.767 million
Source text for Eikon: ID:nCCN7SLvV4
Further company coverage: RX.V
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Biosyent
See all newsCanada's BioSyent Q2 revenue jumps 95% following Oral Health acquisition
Canada's BioSyent Q1 revenue rises helped by Oral Science acquisition
Brief: Biosyent Announces Closing Of The Acquisition Of Oral Science Inc.
Brief: Biosyent To Acquire Oral Science Inc.
Brief: Biosyent Announces Renewal Of Normal Course Issuer Bid